Lastly, GSK321, developed by GlaxoSmithKline, has been shown to decrease intracellular 2HG in primary IDH1-mutant AML cells ex vivo and consequently inhibit cellular proliferation, promote differentiation, and induce global hypomethylation (79). The gene discussed is IDH1; the disease is acute myeloid leukemia.